Datasheet for ABIN2181472

LILRB2 Protein (AA 22-461) (His tag)

1 Image

Go to Product page

Overview

Quantity:	100 µg
Target:	LILRB2
Protein Characteristics:	AA 22-461
Origin:	Human
Source:	HEK-293 Cells
Protein Type:	Recombinant
Purification tag / Conjugate:	This LILRB2 protein is labelled with His tag.

Product Details

Sequence:	AA 22-461
Characteristics:	This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 48.6 kDa. The protein migrates as 60-70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Purity:	>95 % as determined by SDS-PAGE.
Sterility:	0.22 µm filtered
Endotoxin Level:	Less than 1.0 EU per µg by the LAL method.

Target Details

Target:	LILRB2
Alternative Name:	LILRB2 (LILRB2 Products)

Target Details

Background:	Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2) is also known as CD85 antigen-like family member D (CD85d), Immunoglobulin-like transcript 4 (ILT-4), Monocyte / macrophage immunoglobulin-like receptor 10 (MIR-10), which is a member of the the subfamily B class of LIR receptors. LILRB2 is receptor for class I MHC antigens. LILRB2 recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles. LILRB2 competes with CD8A for binding to class I MHC antigens. LILRB2 / CD85d inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.
Molecular Weight:	48.6 kDa
Pathways:	Cellular Response to Molecule of Bacterial Origin

Application Details

Restrictions:	For Research Use only

Handling

Format:	Lyophilized
Buffer:	PBS, pH 7.4
Handling Advice:	Please avoid repeated freeze-thaw cycles.
Storage:	-20 °C
Storage Comment:	No activity loss was observed after storage at: In lyophilized state for 1 year (4 °C), After reconstitution under sterile conditions for 3 months (-70 °C).

Images



SDS-PAGE

Image 1. Human LILRB2, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 92%.